CHK1 inhibitors in combination chemotherapy thinking beyond the cell cycle

Molecular Interventions

Volumn 11, Issue 2, 2011, Pages 133-140

  Dent, Paul ^a,c   Tang, Yong ^a   Yacoub, Adly ^a   Dai, Yun ^b   Fisher, Paul B ^a,c   Grant, Steven ^b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ATM PROTEIN; AZD 7762; BORTEZOMIB; CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 INHIBITOR; CISPLATIN; CYTARABINE; ENZYME INHIBITOR; FLAVOPIRIDOL; GEMCITABINE; LY 2606368; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MULTIPROTEIN COMPLEX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PF 477736; SCH 900776; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CELL CYCLE; CELL CYCLE ARREST; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL CYCLE; CELL DEATH; DRUG THERAPY, COMBINATION; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 79955686677     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.11.2.11     Document Type: Review

References (86)

1. Lonkar P and Dedon PC (2010) Reactive species and DNA damage in chronic inflammation: Reconciling chemical mechanisms and biological fates. Int J Cancer, doi:10.1002/ijc.25815.
2. Boesch P, Weber-Lotfi F, Ibrahim N, Tarasenko V, Cosset A, Paulus F, Lightowlers RN, and Dietrich A (2011) DNA repair in organelles: Pathways, organization, regulation, relevance in disease and aging. Biochim Biophys Acta 1813:186-200.
3. Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, and Khanna KK (2010) Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene 29: 6085-98.
4. Chen F, Wang W, and El-Deiry WS (2010) Current strategies to target p53 in cancer. Biochem Pharmacol 80:724-730.
5. Ciccia A and Elledge SJ (2010) The DNA damage response: Making it safe to play with knives. Mol Cell 40:179-204.
6. Dai Y and Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16:376-383.
7. Smith J, Tho LM, Xu N, and Gillespie DA (2010) The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108:73-112.
8. Chen Y and Poon RY (2008) The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front Biosci 13:5016-5029. (Pubitemid 351599655)
9. Bartek J, Bartkova J, and Lukas J (2007) DNA damage signaling guards against activated oncogenes and tumour progression. Oncogene 26:7773-7779. (Pubitemid 350242463)
10. Choudhury A, Cuddihy A, and Bristow RG (2006) Radiation and new molecular agents part I: Targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 16:51-58. (Pubitemid 41832316)
11. Stracker TH, Usui T, and Petrini JH (2009) Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) 8:1047-1054.
12. Lavecchia A, Di Giovanni C, and Novellino E (2009) CDC25A and B dual-specificity phosphatase inhibitors: Potential agents for cancer therapy. Curr Med Chem 16:1831-1849.
13. Kiyokawa H and Ray D (2008) In vivo roles of CDC25 phosphatases: Biological insight into the anti-cancer therapeutic targets. Anticancer Agents Med Chem 8:832-836.
14. Aressy B and Ducommun B (2008) Cell cycle control by the CDC25 phosphatases. Anticancer Agents Med Chem 8:818-824.
15. Satyanarayana A and Kaldis P (2009) Mammalian cell-cycle regulation: Several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 28:2925-2939.
16. Stark GR and Taylor WR (2006) Control of the G2/M transition. Mol Biotechnol 32:227-248.
17. Derheimer FA and Kastan MB (2010) Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett 584:3675-3681.
18. Lavin MF (2008) Ataxia-telangiectasia: From a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9:759-769.
19. Reinhardt HC and Yaffe MB (2009) Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 21:245-255.
20. Chen Y and Poon RY (2008) The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front Biosci 13:5016-5029. (Pubitemid 351599655)
21. Takahashi I, Kobayashi E, Asano K, Yoshida M, and Nakano H (1987) UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J Antibiot (Tokyo) 40:1782-1784. (Pubitemid 18023359)
22. Wang Q, Worland PJ, Clark JL, Carlson BA, and Sausville EA (1995) Apoptosis in 7-hydroxy-staurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 6:927-936.
23. Bunch RT and Eastman A (1996) Enhancement of cisplatininduced cytotoxicity by 7-hydroxy-staurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 2:791-797. (Pubitemid 26168931)
24. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, and O'Connor PM (1996) UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88:956-965. (Pubitemid 26239383)
25. Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, and Grant S (1997) Agents that downregulate or inhibit protein kinase C circumvent resistance to 1-beta-Darabinofuranosylcytosine- induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol 52:1000-1009. (Pubitemid 28013718)
26. Tse AN and Schwartz GK (2004) Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res 64:6635-6644. (Pubitemid 39297924)
27. Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gonen M, O'reilly E, Kemeny N, et al. (2005) Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxy-staurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 23:1875-1884. (Pubitemid 46211365)
28. of the Chk1- mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 61:5843-5849.
29. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, and Piwnica-Worms H (2000) The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN- 01. J Biol Chem 275:5600-5605. (Pubitemid 30115197)
30. Komander D, Kular GS, Bain J, Elliott M, Alessi DR, and Van Aalten DM (2003) Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 375:255-262. (Pubitemid 37315433)
31. Fuse E, Hashimoto A, Sato N, Tanii H, Kuwabara T, Kobayashi S, and Sugiyama Y (2000) Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein. Pharm Res 17:553-564. (Pubitemid 30416393)
32. Kurata N, Imabeppu S, Nitoh M, Kobayashi H, Kuwabara T, and Kobayashi S (2000) The effect of different dosing schedules of UCN- 01 on its pharmacokinetics and cardiohaemodynamics in dogs. J Pharm Pharmacol 52:1327-1335.
33. Dees EC, Baker SD, O'Reilly S, Rudek MA, Davidson SB, Aylesworth C, Elza-Brown K, Carducci MA, and Donehower RC (2005) A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin Cancer Res 11:664-671. (Pubitemid 40116893)
34. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, et al. (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7:2955-2966.
35. Ashwell S, Janetka JW, and Zabludoff S (2008) Keeping checkpoint kinases in line: New selective inhibitors in clinical trials. Expert Opin Investig Drugs 17:1331-1340.
36. Daud A, Springett GM, Mendelson DS, Munster PN, Goldman JW, Strosberg JR, Kato G, Nesheiwat T, Isaacs R, and Rosen LS (2010) A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors. J Clin Oncol 28(15), supp: 3064.
37. http://clinicaltrials.gov/ct2/show/NCT01115790.
38. Dent P, Curiel DT, Fisher PB, and Grant S (2009) Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy. Drug Resist Updat 12:65-73.
39. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, and Schmidt-Ullrich R (1999) Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10:2493-2506. (Pubitemid 29393505)
40. Reardon DB, Contessa JN, Mikkelsen RB, Valerie K, Amir C, Dent P, and Schmidt-Ullrich RK (1999) Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 18:4756-4766. (Pubitemid 29417751)
41. Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, and Dent P (2007) Radiation-induced cell signaling: Inside-out and outside- in. Mol Cancer Ther 6:789-801. (Pubitemid 46554549)
42. Grant S and Dent P (2007) Simultaneous interruption of signal transduction and cell cycle regulatory pathways: Implications for new approaches to the treatment of childhood leukemias. Curr Drug Targets 8:751-759. (Pubitemid 47603404)
43. Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R, Dent P, and Grant S (2001) Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 61:5106-5115. (Pubitemid 32681542)
44. McKinstry R, Qiao L, Yacoub A, Dai Y, Decker R, Holt S, Hagan MP, Grant S, and Dent P (2002) Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. Cancer Biol Ther 1:243-253.
45. Mitchell C, Park M, Eulitt P, Yang C, Yacoub A, and Dent P (2010) Poly (ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells. Mol Pharmacol 78:909-917.
46. Pei XY, Li W, Dai Y, Dent P, and Grant S (2006) Dissecting the roles of checkpoint kinase 1/CDK1 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells. Mol Pharmacol 70:1965-1973. (Pubitemid 44771912)
47. Mogila V, Xia F, and Li WX (2006) An intrinsic cell cycle checkpoint pathway mediated by MEK and ERK in Drosophila. Dev Cell 11:575-582. (Pubitemid 44430898)
48. Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, Kramer LB, Dent P, and Grant S (2011) Disruption of Src function potentiates Chk1 inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood 117:1947-1957.
49. Dai Y, Landowski TH, Rosen ST, Dent P, and Grant S (2002) Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 100:3333-3343. (Pubitemid 35217085)
50. Yu C, Dai Y, Dent P, and Grant S (2002) Coadministration of UCN- 01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571. Cancer Biol Ther 1:674-682.
51. Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P, and Grant S (2003) Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 102:1824-1832. (Pubitemid 37022579)
52. Dai Y, Pei XY, Rahmani M, Conrad DH, Dent P, and Grant S (2004) Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 103:2761-2770. (Pubitemid 38393035)
53. Dai Y, Dent P, and Grant S (2003) Tumor necrosis factor-related apoptosis- inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL. Mol Pharmacol 64:1402-1409. (Pubitemid 37532230)
54. Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C, Dent P, and Grant S (2005) Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 105:1706-1716. (Pubitemid 40223694)
55. Hahn M, Li W, Yu C, Rahmani M, Dent P, and Grant S (2005) Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 4:457-470. (Pubitemid 40443931)
56. Pei XY, Dai Y, Rahmani M, Li W, Dent P, and Grant S (2005) The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. Clin Cancer Res 11:4589-4600. (Pubitemid 40825650)
57. Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, et al. (2005) Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biol Ther 4:1275-1284.
58. Dai Y, Khanna P, Chen S, Pei XY, Dent P, and Grant S (2007) Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood 109:4415-4423. (Pubitemid 46743411)
59. H, Dent P, and Grant S (2007) MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood 110:2092-2101. (Pubitemid 47443927)
60. Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, Dai Y, Hagan MP, Roberts JD, Yacoub A, et al. (2008) Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Mol Cancer Ther 7:616-629. (Pubitemid 351482144)
61. Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, Dent P, and Grant S (2008) Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 112:2439-2449.
62. Mitchell C, Hamed HA, Cruickshanks N, Tang Y, Bareford MD, Hubbard N, Tye G, Yacoub A, Dai Y, Grant S, et al. (2011) Simultaneous exposure of transformed cells to SRC family Inhibitors and CHK1 inhibitors causes cell death. Unpublished results.
63. Borysov SI and Guadagno TM (2008) A novel role for Cdk1/cyclin B in regulating B-raf activation at mitosis. Mol Biol Cell 19:2907-2915.
64. Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, and Valerie K (2007) Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 67:1046-1053.
65. Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, Chong WY, Hummersone M, Rigoreau L, Menear KA, et al. (2009) Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther 8:2894-2902.
66. Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, and Delia D (2007) Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 6:935-944. (Pubitemid 46554563)
67. Perona R, Moncho-Amor V, Machado-Pinilla R, Belda-Iniesta C, and Sánchez Pérez I (2008) Role of CHK2 in cancer development. Clin Transl Oncol 10:538-542.
68. Gaul L, Mandl-Weber S, Baumann P, Emmerich B, and Schmidmaier R (2008) Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: The role of ATM-Chk2-Cdc25A and ATM-p53-p21- pathways. J Cancer Res Clin Oncol 134:245-253. (Pubitemid 350234070)
69. Oguri T and Lazo JS (2004) Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells. Prostate 58:95-102. (Pubitemid 38057993)
70. Chow JP, Siu WY, Fung TK, Chan WM, Lau A, Arooz T, Ng CP, Yamashita K, and Poon RY (2003) DNA damage during the spindleassembly checkpoint degrades CDC25A, inhibits cyclin-CDK1 complexes, and reverses cells to interphase. Mol Biol Cell 14:3989-4002. (Pubitemid 37186303)
71. Donaldson KL, Goolsby GL, Kiener PA, and Wahl AF (1994) Activation of p34cdk1 coincident with taxol-induced apoptosis. Cell Growth Differ 5:1041-1050. (Pubitemid 24312279)
72. Martin SJ, McGahon AJ, Nishioka WK, LaFace D, Guo X, Th'ng J, Bradbury EM, and Green DR (1995) p34cdk1 and apoptosis. Science 269:106-107.
73. Wang R, Jung SY, Wu CF, Qin J, Kobayashi R, Gallick GE, and Kuang J (2010) Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation. Proc Natl Acad Sci USA 107:19885-19890.
74. Ma CX, Janetka JW, and Piwnica-Worms H (2011) Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med (2):88-96
75. Isoda M, Kanemori Y, Nakajo N, Uchida S, Yamashita K, Ueno H, and Sagata N (2009) The extracellular signal-regulated kinase-mitogenactivated protein kinase pathway phosphorylates and targets Cdc25A for SCF beta-TrCP-dependent degradation for cell cycle arrest. Mol Biol Cell 20:2186-2195.
76. Harley ME, Allan LA, Sanderson HS, and Clarke PR (2010) Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdk10- dependent destruction during mitotic arrest. EMBO J 29:2407-2420.
77. Terrano DT, Upreti M, and Chambers TC (2010) Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 30:640-656.
78. Cheng P, Li Y, Yang L, Wen Y, Shi W, Mao Y, Chen P, Lv H, Tang Q, and Wei Y (2009) Hepatitis B virus X protein (HBx) induces G2/M arrest and apoptosis through sustained activation of cyclin B1-CDK1 kinase. Oncol Rep 22:1101-1107.
79. Konishi Y and Bonni A (2003) The E2F-Cdk1 cell-cycle pathway specifically mediates activity deprivation-induced apoptosis of postmitotic neurons. J Neurosci 23:1649-1658. (Pubitemid 36314720)
80. Huber A, Bai P, de Murcia JM, and de Murcia G (2004) PARP-1, PARP-2 and ATM in the DNA damage response: Functional synergy in mouse development. DNA Repair (Amst) 3:1103-1108. (Pubitemid 38997953)
81. Hagan MP, Yacoub A, and Dent P (2007) Radiation-induced PARP activation is enhanced through EGFR-ERK signaling. J Cell Biochem 101:1384-1393. (Pubitemid 47242770)
82. Javvadi P, Hertan L, Kosoff R, Datta T, Kolev J, Mick R, Tuttle SW, and Koumenis C (2010) Thioredoxin reductase-1 mediates curcumininduced radiosensitization of squamous carcinoma cells. Cancer Res 70:1941-1950.
83. Shukla A, Hillegass JM, Macpherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR, and Mossman BT (2010) Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer 9:314-327.
84. Yacoub A, Gilfor D, Hawkins W, Park MA, Hanna D, Hagan MP, Curiel DT, Fisher PB, Grant S, and Dent P (2006) MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo. Cancer Biol Ther 5:1332-1339. (Pubitemid 44772260)
85. Pan ZZ, Bruening W, Giasson BI, Lee VM, and Godwin AK (2002) Gamma-synuclein promotes cancer cell survival and inhibits stressand chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem 277:35050-35060.
86. Burris H 3rd, and Rocha-Lima C (2008) New therapeutic directions for advanced pancreatic cancer: Targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13:289-298. (Pubitemid 351679904)